Inclusion Criteria:

- Diagnosis of MS and cranial MRI scan demonstrating white matter lesions attributable
to MS within 5 years

- Onset of MS symptoms within 5 years

- EDSS score 0.0 to 3.0

- ≥2 MS attacks within 24 months, with ≥1 attack within 12 months

Exclusion Criteria:

- Received prior therapy for MS other than corticosteroids

- Exposure to immunosuppressive or immunomodulatory agents other than systemic
corticosteroid treatment

- Received treatment with a monoclonal antibody for any reason

- Previous treatment with any investigational drug (i.e. medication that is not
approved at any dose for any indication)

- Has any progressive form of MS

- Any disability acquired from trauma or another illness that could interfere with
evaluation of disability due to MS

- Major systemic disease that cannot be treated or adequately controlled by therapy

- Active infection or high risk for infection

- Autoimmune disorder (other than MS)

- Impaired hepatic or renal function

- History of malignancy, except basal skin cell carcinoma

- Medical, psychiatric, cognitive, or other conditions that compromise the patient's
ability to understand the patient information, to give informed consent, to comply
with the trial protocol, or to complete the study

- Known bleeding disorder

- Of childbearing potential with a positive serum pregnancy test, pregnant or lactating

- Current participation in another clinical study

- Previous hypersensitivity reaction to any immunoglobulin product

- Known allergy or intolerance to interferon beta, human albumin, or mannitol

- Intolerance of pulsed corticosteroids, especially a history of steroid psychosis

- Inability to self-administer subcutaneous (SC) injections or receive SC injections
from caregiver

- Inability to undergo MRI with gadolinium administration

- Unwilling to use a reliable and acceptable contraceptive method throughout the study
period (fertile patients only)